Digna Biotech S.L.   Report issue

For profit Phase 1 Phase 2
Founded: Madrid Spain (2003)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2007
NCT00656825
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (3)

interferon alpha-2b (Intron-A) (1 trial)

interferon alpha-5 (1 trial)

p144 (3 trials)

Drugs in Phase 1 Trials (2)

cardiotrophin-1 (1 trial)

raav2/5-pbgd (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Porphyria, Acute Intermittent (Phase 1)

Porphyria, Erythropoietic (Phase 1)

Porphyrias (Phase 1)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Sclerosis (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 5